Citigroup’s Takeda Pharmaceutical TAK Stock Holding History

Citigroup’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-400,000	Closed	-$5.45M	–	6591
2021 Q4	$5.45M	Hold	400,000	–	–	﹤0.01%	1765
2021 Q3	$6.55M	Hold	400,000	–	–	﹤0.01%	1632
2021 Q2	$6.73M	Hold	400,000	–	–	﹤0.01%	1681
2021 Q1	$7.3M	Buy	400,000 +104,596	+35%	+$1.88M	﹤0.01%	1560
2020 Q4	$5.38M	Sell	295,404 -16,300	-5%	-$286K	﹤0.01%	2034
2020 Q3	$5.56M	Sell	311,704 -56,200	-15%	-$1.02M	﹤0.01%	1817
2020 Q2	$6.6M	Buy	367,904 +51,000	+16%	+$916K	0.01%	1630
2020 Q1	$4.81M	Sell	316,904 -100,911	-24%	-$1.83M	﹤0.01%	1705
2019 Q4	$8.24M	Sell	417,815 -47,300	-10%	-$905K	0.01%	1638
2019 Q3	$8M	Sell	465,115 -38,796	-8%	-$671K	0.01%	1560
2019 Q2	$8.92M	Buy	503,911 +143,293	+40%	+$2.61M	0.01%	1483
2019 Q1	$7.35M	Buy	+360,618	New	+$7.26M	0.01%	1487

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup's TAK Position: Q1 2026 in Review

Citigroup increased its Takeda Pharmaceutical (TAK) stake by 1,778% in Q1 2026, buying an estimated $5.95M and bringing the position to 358,174 shares worth $6.63M. The position accounts for ﹤0.01% of the portfolio, ranked #1749.

Citigroup first reported a position in TAK in Q4 2018 and has held it in 30 quarters since. The position peaked at $113M in Q4 2018. 358 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

Citigroup held 358,174 shares of Takeda Pharmaceutical worth $6.63M as of Q1 2026.
Citigroup bought 339,104 Takeda Pharmaceutical shares in Q1 2026, an estimated $5.95M.
Takeda Pharmaceutical made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #1749 holding.
Citigroup first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 30 quarters since.
Citigroup's Takeda Pharmaceutical position peaked at $113M in Q4 2018.
358 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.